Xarelto clinical trials may have been faulty

Clinical trials performed by Johnson & Johnson and Bayer pharmaceuticals may have shown the drug Xaralto to be safer than it actually is.

Xaralto is an anti-clotting drug frequently prescribed to prevent strokes in patients with heart disorders. The Food and Drug Administration is investigating whether a faulty blood monitor device used in the clinical trials of the drug skewed testing results.

See the New York Times report on this issue here.